Login to Your Account

NiCox Closes Out €100M Fund with €70M Discounted Rights

By Cormac Sheridan

Wednesday, December 23, 2009

No Abstract


BioWorld Today Correspondent


NiCox SA completed the second leg of a two-part €100 million (US$143.2 million) fundraising by raising €69.9 million in a discounted rights offering, a financing that the firm believes will be the last it needs.

One reason why came shortly afterward when NiCox filed for approval of naproxcinod in osteoarthritis with the European Medicines Agency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription